Status:
COMPLETED
Ampicillin for DYT-1 Dystonia Motor Symptoms
Lead Sponsor:
University of Florida
Collaborating Sponsors:
Tyler's Hope for a Dystonia Cure, Inc
Conditions:
DYT-1
Dystonia
Eligibility:
All Genders
7-80 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate if the antibiotic Ampicillin is safe and tolerated in patients that have generalized dystonia caused by the DYT-1 gene mutation, as compared to patients treate...
Detailed Description
This is a double-blinded and randomized drug study: neither the patient nor the investigator know if patients are taking study drug (Ampicillin) or placebo. Three study visits will include neurologic...
Eligibility Criteria
Inclusion
- DYT-1 dystonia, confirmed by genetic testing
- Between ages of 7 and 80 years
- BFM-DRS score greater than 6
Exclusion
- Negative DYT-1 dystonia gene test
- Allergy to penicillins or cephalosporins
- Concurrent bacterial, viral or fungal infection at time of enrollment
- Pregnancy
- Inability to follow study protocol
- Lactose intolerance (placebo contains lactose powder)
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2017
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT01433757
Start Date
September 1 2011
End Date
June 1 2017
Last Update
July 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UF Center for Movement Disorders and Neurorestoration
Gainesville, Florida, United States, 32607